


Low Immunogenicity

High gene expression

New Biocompatible Polymer (for DDS)

A novel biocompatible polymer "PGLMMA" offers numerous advantages, such as being less likely to induce IgM antibody production and maintaining blood retention even after multiple doses.




Example

- Hydrophilize surface of particles
- Form hydrophilic micelles

Biocompatible polymer **PGLMMA**

Average molecular weight (Mw) of about 12,000



*PGLMMA is an abbreviation for poly (glycerol monomethacrylate).

Features

1

IgM antibody production is low.

2

Retention in blood is maintained even after multiple doses.

3



Even if the surface is hydrophilic, it is easily taken up by cancer cells.

4

Safety concerns such as acute toxicity are low.

IgM antibody production

➡ **PGLMMA-modified liposomes induce little IgM antibody.**




Retention in blood after multiple doses

➡ PGLMMA-modified liposomes showed no decrease in blood retention after the second dose.

Animal species : BALB/cCrSlc mice
Administration method : Tail vein injection , 2 doses
Drug : Polymer-modified liposomes(About 60 nm, in PBS, Dil staining)
Dose : First 0.1 $\mu\text{mol/kg}$
Second 5 $\mu\text{mol/kg}$
Dosing interval : 7 days

Study group	Modification of the drugs	
	1st	2nd
PEG once	PBS	PEG
PEG twice	PEG	PEG
PGLMMA once	PBS	PGLMMA
PGLMMA twice	PGLMMA	PGLMMA
PEG \rightarrow PGLMMA	PEG	PGLMMA




The particle size of polymer-modified liposomes is about 60 nm.



Cellular Uptake and Gene Expression

➡ PGLMMA-modified particles are easily taken up by cancer cells.

Polymer-modified lipid nanoparticles (LNP) encapsulating fluorescent dye and Luc mRNA



※ MCF-7 : human breast cancer cell
A549 : human lung cancer cell
S2-013 : human pancreatic cancer cell

Safety studies

➡ No toxic findings in acute toxicity and Ames studies.

Items	Study details	Results
Single dose in rats (acute toxicity) study	Study category : Non-GLP study Study group : 3 males and 3 females per group Route of administration : Intravenous administration Dosage : 10 or 100 mg/kg Evaluation items : General symptoms, body weight, necropsy Observation period : 14 days	No findings
Ames tests	Study category : GLP study (Industrial Safety and Health Act, Chemical Substances Control Law, OECD) Guideline : OECD-TG471 Strains : TA98, TA100, TA1535, TA1537, and WP2uvrA	Negative